Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Beginning Cash Balance: 2009-2022

Historic Beginning Cash Balance for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Dec 2022 value amounting to -$13.3 million.

  • Avadel Pharmaceuticals' Beginning Cash Balance fell 122.81% to -$13.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$23.3 million, marking a year-over-year decrease of 132.45%. This contributed to the annual value of -$20.2 million for FY2024, which is 147.19% down from last year.
  • Avadel Pharmaceuticals' Beginning Cash Balance amounted to -$13.3 million in Q4 2022, which was down 124.51% from $54.1 million recorded in Q3 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Beginning Cash Balance peaked at $102.2 million during Q3 2020, and registered a low of -$13.3 million during Q4 2022.
  • Its 3-year average for Beginning Cash Balance is $56.4 million, with a median of $60.0 million in 2021.
  • In the last 5 years, Avadel Pharmaceuticals' Beginning Cash Balance spiked by 663.30% in 2020 and then tumbled by 122.81% in 2022.
  • Avadel Pharmaceuticals' Beginning Cash Balance (Quarterly) stood at $17.8 million in 2018, then declined by 27.86% to $12.9 million in 2019, then surged by 545.91% to $83.1 million in 2020, then slumped by 30.01% to $58.2 million in 2021, then tumbled by 122.81% to -$13.3 million in 2022.
  • Its Beginning Cash Balance stands at -$13.3 million for Q4 2022, versus $54.1 million for Q3 2022 and $60.9 million for Q2 2022.